Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 12Colorectal Neoplasms 9Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Pancreatic Neoplasms 3Colonic Neoplasms 3Skin Neoplasms 2Skin Diseases 2Rectal Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Spinocerebellar Degenerations 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumor 1Soft Tissue Neoplasms 1Recurrence 1Peripheral Nervous System Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Noonan Syndrome 5 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × binimetinib × Clear all
NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Array BioPharma

Phase 1 Completed
89 enrolled
BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡